Dr. Yongki Choi
Dr. Choi’s research aims to develop a novel, electronic-based platform that can selectively detect individual target biomarkers of pancreatic cancer in blood by integrating cutting-edge nanotechnology and cancer biology. This research will offer a highly reliable, accurate, automated identification and classification strategy of pancreatic cancer, allowing early-detection, prediction of organ-specific metastasis, and selection of an effective, specific therapeutic plan for the pancreatic cancer patients.
Dr. Jansen’s project aims to identify the epigenetic and genetic markers which are important in the development and progression of pancreatic cancer from existing public and clinic based resources. Using these pancreatic cancer associated sets and samples, Dr. Jansen’s group will incorporate clinical-based risk factor data to further understand the biology behind the development and growth of pancreatic cancer. The results of this work will shape a framework for integrative epigenetic-genetic-clinical analysis in future epidemiologic study designs where the objective is identifying key marker sets which can used to screen for early disease or which can be targeted for effective treatment.
Dr. Kim's research is focused on investigating the perivascular heterogeneity in Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Microenvironment (TME). The research is aiming to identify novel mechanisms to reprogram the perivascular signature that will promote vascular functionality and enhance drug delivery efficacy. The Kim group utilize in vitro cell culture system to study mechanistic details and animal model system including various Genetically Engineered Mouse Models (GEMM), to evaluate the efficacy of new findings in vivo.